{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05957367",
            "orgStudyIdInfo": {
                "id": "DCC-3116-01-002"
            },
            "organization": {
                "fullName": "Deciphera Pharmaceuticals LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies",
            "officialTitle": "A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-of-dcc-in-combination-with-anticancer-therapies-in-participants-with-advanced-malignancies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-07-14",
            "studyFirstSubmitQcDate": "2023-07-14",
            "studyFirstPostDateStruct": {
                "date": "2023-07-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-30",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-31",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Deciphera Pharmaceuticals LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of DCC-3116 with other anticancer agents."
        },
        "conditionsModule": {
            "conditions": [
                "GIST"
            ],
            "keywords": [
                "DCC-3116",
                "Advanced gastrointestinal stromal tumors",
                "gastrointestinal stromal tumors",
                "ripretinib"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 94,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Escalation (Part 1, Module A)",
                    "type": "EXPERIMENTAL",
                    "description": "Escalation Module A Part 1 DCC-3116 combination closed on January 8, 2024, with no participants enrolled.",
                    "interventionNames": [
                        "Drug: DCC-3116"
                    ]
                },
                {
                    "label": "Expansion (Part 2, Module A)",
                    "type": "EXPERIMENTAL",
                    "description": "Expansion Module A Part 2 DCC-3116 combination closed on January 8, 2024, with no participants enrolled.",
                    "interventionNames": [
                        "Drug: DCC-3116"
                    ]
                },
                {
                    "label": "Dose Escalation (Part 1, Module B)",
                    "type": "EXPERIMENTAL",
                    "description": "DCC-3116 tablets in escalating dose cohorts in 28-day cycles will be administered in combination with ripretinib once daily (QD).",
                    "interventionNames": [
                        "Drug: DCC-3116",
                        "Drug: Ripretinib"
                    ]
                },
                {
                    "label": "Expansion (Part 2, Module B)",
                    "type": "EXPERIMENTAL",
                    "description": "DCC-3116 tablets will be administered in combination with ripretinib in 28-day cycles to evaluate preliminary efficacy in participants with 2nd-line advanced gastrointestinal stromal tumor (GIST).",
                    "interventionNames": [
                        "Drug: DCC-3116",
                        "Drug: Ripretinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "DCC-3116",
                    "description": "Oral Tablet Formulation",
                    "armGroupLabels": [
                        "Dose Escalation (Part 1, Module A)",
                        "Dose Escalation (Part 1, Module B)",
                        "Expansion (Part 2, Module A)",
                        "Expansion (Part 2, Module B)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ripretinib",
                    "description": "Oral Tablet Formulation",
                    "armGroupLabels": [
                        "Dose Escalation (Part 1, Module B)",
                        "Expansion (Part 2, Module B)"
                    ],
                    "otherNames": [
                        "QINLOCK, DCC-2618"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Adverse Events (Escalation Phase)",
                    "description": "Identify the observed adverse events and serious adverse events associated with DCC-3116 in combination with other anticancer therapies.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Recommended Phase 2 Doses (RP2D) (Escalation Phase)",
                    "description": "Identify the dose-limiting toxicities for each dose level tested and determine the recommended Phase 2 doses of DCC-3116 in combination with other anticancer therapies.",
                    "timeFrame": "Approximately 18 months"
                },
                {
                    "measure": "Objective response rate (ORR) (Expansion Phase)",
                    "description": "Proportion of participants who achieve CR or PR per histology-specific consensus response criteria.",
                    "timeFrame": "Approximately 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Duration of response (DoR)",
                    "description": "DoR is defined as the time interval from the time that the measurement criteria are first met for CR or PR (whichever is first recorded) per histology-specific consensus response criteria until the first date that the progressive disease is objectively documented or death, whichever occurs first.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Disease Control Rate (DCR)",
                    "description": "The DCR is defined as the proportion of participants who achieve CR, PR, or stable disease (SD) per histology-specific consensus response criteria.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Time to response",
                    "description": "Time to response is defined as the time from initiation of treatment until the first assessment demonstrating CR or PR per histology-specific consensus response criteria.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Progression-free survival (PFS)",
                    "description": "PFS is defined as the time from initiation of treatment until documented disease progression per histology-specific consensus response criteria or death, whichever occurs first.",
                    "timeFrame": "Approximately 24 months"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "description": "OS is defined as the time from initiation of treatment until death.",
                    "timeFrame": "Approximately 48 months"
                },
                {
                    "measure": "Maximum observed concentration (Cmax)",
                    "description": "Measure the maximum observed concentration of DCC-3116 combinations.",
                    "timeFrame": "Predose and up to 12 hours postdose"
                },
                {
                    "measure": "Time to maximum observed concentration (Tmax)",
                    "description": "Measure the time to maximum plasma concentration of DCC-3116 combinations.",
                    "timeFrame": "Predose and up to 12 hours postdose"
                },
                {
                    "measure": "Minimum observed concentration (Cmin)",
                    "description": "Measure the minimum observed concentration of DCC-3116 combinations.",
                    "timeFrame": "Predose and up to 12 hours postdose"
                },
                {
                    "measure": "Area under the concentration-time curve (AUC)",
                    "description": "Measure the AUC of DCC-3116 combinations.",
                    "timeFrame": "Predose and up to 12 hours postdose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female \u226518 years of age\n* Module A: Part 1 and Part 2:\n\nModule A Part 1 and Part 2 DCC-3116 combination closed on January 8, 2024, with no participants enrolled.\n\n* Module B: Only for Part 1 (Safety/Dose-finding):\n\n  * Pathologically confirmed diagnosis of GIST with a KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation\n  * Must have progressed on at least one approved systemic regimen given in the locally advanced or metastatic setting or have documented intolerance to it\n  * Must not have received prior ripretinib treatment\n* Module B: Only for Part 2 (Expansion)\n\n  * Pathologically confirmed GIST with documented mutation in KIT exon 11\n  * Must have progressed on imatinib given in the locally advanced or metastatic setting or have been intolerant to imatinib and may not have received additional systemic therapy for GIST\n* Measurable disease\n* Must have a life expectancy of more than 3 months and an ECOG performance status of 0-1\n* Adequate organ function and bone marrow reserve based on laboratory assessments performed at Screening\n* Must provide a fresh tumor biopsy and an archival tumor tissue sample, if available\n* Must agree to provide an on treatment biopsy\n\nExclusion Criteria:\n\n* Must not have received the following within the specified time periods prior to the first dose of study drug:\n\n  1. Medications, including anticancer therapies, that are known strong or moderate inhibitors or inducers of CYP3A4 or P-glycoprotein (P-gp) including certain herbal medications (eg, St. John's wort): 14 days or 5\u00d7the half-life of the medication (whichever is longer)\n  2. Other anticancer therapies and any investigational therapies with a known safety and PK profile: 14 days or 5\u00d7the half-life of the medication (whichever is shorter)\n  3. Investigational therapies with unknown safety and PK profile: 28 days. If there is enough data on the investigational therapy to assess the risk for drug-drug interactions and late toxicities of prior therapy as low, the Sponsor's Medical Monitor may approve a shorter washout of 14 days\n  4. Grapefruit or grapefruit juice: 14 days\n* Have not recovered from all clinically relevant toxicities from prior therapy\n* New York Heart Association Class III or IV heart disease, active ischemia, or any other uncontrolled cardiac condition, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, congestive heart failure, or myocardial infarction within 6 months prior to the first dose of study drug\n* Symptomatic central nervous system (CNS) metastases or presence of leptomeningeal disease\n* Malabsorption syndrome\n* Bone disease that requires ongoing treatment or has required treatment within 6 months of signing the informed consent form\n* Radiation for indications other than bone disease must have been completed 4 weeks prior to first dose of study drug, unless it consisted of limited field palliative radiation, including whole brain radiation, which must have been completed at least 2 weeks prior to first dose of study drug\n* Major surgery within 4 weeks of the first dose of study drug\n* Active HIV, Hepatitis B or Hepatitis C infection",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Team",
                    "role": "CONTACT",
                    "phone": "785-830-2100",
                    "email": "Clinicaltrials@deciphera.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Team",
                    "affiliation": "Deciphera Pharmaceuticals LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCLA Department of Medicine-Hematology/Oncology",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jacqueline Banuelos",
                            "role": "CONTACT",
                            "phone": "310-869-7014",
                            "phoneExt": "16108",
                            "email": "jbanuelosmurillo@mednet.ucla.edu"
                        },
                        {
                            "name": "Arun Singh, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Sylvester Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nailet Bestard",
                            "role": "CONTACT",
                            "phone": "305-243-8173",
                            "email": "nxr518@med.miami.edu"
                        },
                        {
                            "name": "Jonathan C Trent, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "START Midwest",
                    "status": "RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49546",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Julie Burns",
                            "role": "CONTACT",
                            "phone": "616-954-5559",
                            "email": "julie.burns@startmidwest.com"
                        },
                        {
                            "name": "Sreenivasa Chandana, M.D., Ph.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "Laura & Isaac Perlmutter Cancer Center at NYU Langone Health",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Phase 1 Screening",
                            "role": "CONTACT",
                            "phone": "212-731-5654",
                            "email": "Phase1Screening@nyulangone.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center - Main Campus",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Pragya Khadka",
                            "role": "CONTACT",
                            "email": "khadkap1@mskcc.org"
                        },
                        {
                            "name": "Melessa Hardayal",
                            "role": "CONTACT",
                            "email": "hardayam@mskcc.org"
                        },
                        {
                            "name": "Ping Chi, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Cleveland Clinic Taussig Cancer Center",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Cancer Answer",
                            "role": "CONTACT",
                            "phone": "216-444-7923",
                            "email": "canceranswer@ccf.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Oregon Health & Science University",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Knight Cancer Institute Clinical Trials",
                            "role": "CONTACT",
                            "phone": "503-494-1080",
                            "email": "trials@ohsu.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Fox Chase Cancer Center",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19111",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Refiola Memushi",
                            "role": "CONTACT",
                            "phone": "215-728-3564",
                            "email": "Refiola.Memushi@fccc.edu"
                        },
                        {
                            "name": "Margaret von Mehren, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M25642",
                    "name": "Gastrointestinal Stromal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "T2444",
                    "name": "Gastrointestinal Stromal Tumors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}